- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05318326
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
19 de abril de 2022 actualizado por: Chengdu Easton Biopharmaceuticals Co,Ltd
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets in Chinese Patients With Type 2 Diabetes Mellitus and Poor Diet and Exercise Control
The purpose of this study is to assess the efficacy of Yogliptin (as monotherapy) compared with placebo after 24 weeks, and the safety (up to 52 weeks) of Yogliptin in Chinese patients with Type 2 diabetes who are insufficient glycaemic control with diet and exercise.
Descripción general del estudio
Estado
Reclutamiento
Condiciones
Intervención / Tratamiento
Descripción detallada
The treatment period is composed of a 24-week double-blind period (week 1-24) and a 28-week open-label period (week 25-52).
During the double-blind period, participants will receive 200 mg or 400 mg dose of Yogliptin and matching placebo, or placebo only.
During the open-label period, all participants will receive 400 mg dose of Yogliptin.
Tipo de estudio
Intervencionista
Inscripción (Anticipado)
450
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: yunju Yi
- Número de teléfono: +8613518115493
- Correo electrónico: yiyunju@eastonpharma.cn
Ubicaciones de estudio
-
-
Beijing
-
Beijing, Beijing, Porcelana
- Reclutamiento
- Beijing Hospital
-
Contacto:
- Lixin Guo
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 75 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- 1.Men or women aged 18 to 75 years old at the day of signing the informed consent;
- 2.Type 2 diabetes patients who meet the diagnostic criteria for diabetes issued byChinese Guidelines for the Prevention and Treatment of Type 2 Diabetesin 2020;
- 3.Receive at least 8 weeks of diet and exercise treatment before screening;Not treated with any antidiabetic drugs within 8 weeks before screening;
4.Glycated hemoglobin (HbA1c): Screening period: HbA1c 7.5% to 11% (tested by the research center), when randomly enrolled: HbA1c 7.0% to 10.5% (central laboratory test) Measurement);
5.fasting blood glucose(FPG): Screening period: FPG≤15.0mmol/L (tested by the research center), when randomly enrolled: FPG≤15.0mmol/L (central laboratory test) Measurement);
- 6.Screening period Body mass index(BMI) 19.0kg/m2 to 35.0kg/m2 ;
- 7.Agree to maintain the same diet and exercise habits throughout the trial and be willing and able to accurately use a home blood glucose meter for self-monitoring and recording of blood glucose
- 8.Can understand the procedures and methods of this study, willing to strictly abide by the clinical trial protocol to complete this trial, and voluntarily sign an informed consent.
Exclusion Criteria:
- 1.Non-type 2 diabetes: such as type 1 diabetes, secondary diabetes or other special types of diabetes ;
- 2.History or condition of any of the following at screening or run-in:Those who have a history of diabetic ketoacidosis, hyperglycemia and hyperosmolarity, lactic acidosis and other acute complications of diabetes within 6 months before screening;
- 3.History or condition of any of the following at screening or run-in:Unstable condition or severe diabetic complications such as proliferative retinopathy or maculopathy, severe diabetic neuropathy, intermittent claudication, diabetic foot in the past 6 months;
- 4.History or condition of any of the following at screening or run-in:Three or more episodes of grade 3 hypoglycemia in the past 6 months (according to the diagnostic criteria for hypoglycemia in the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition)) ;
- 5.History or condition of any of the following at screening or run-in:Unstable angina, stroke or transient ischemic attack, myocardial infarction, coronary artery bypass graft or percutaneous coronary intervention (diagnostic angiography is allowed of);
- 6.History or condition of any of the following at screening or run-in:Hemorrhagic stroke or ischemic stroke within the past 6 months, and is not suitable for this clinical trial judged by the investigator ;
- 7. History or condition of any of the following at screening or run-in:Previous history of other serious endocrine diseases affecting glucose metabolism, such as multiple endocrine neoplasia, limb hypertrophy syndrome, Cushing's syndrome, etc., which are not suitable for this clinical trial judged by the ;
- 8. History or condition of any of the following at screening or run-in:Patients with previous severe digestive system diseases, nutritional metabolic diseases and rheumatic diseases, who are not suitable to participate in this clinical trial as judged by the investigator;
- 9. any of the following medical history or conditions at screening or run-in: current thyroid dysfunction not controlled with stable drug dose, and clinically significant abnormalities in thyroid function test results at screening
- 10 Any of the following medical history or conditions at screening or run-in: History or presence of malignancy (except for malignancies that have not recurred in the last 5 years)
- 11 History or condition of any of the following at screening or run-in: Presence of significant psychiatric disorder or speech disorder Unwilling or unable to fully understand and collaborate Contacts and Locations
- 12 Any of the following medical history or conditions at screening or run-in: significant infection or major surgery within 6 months prior to screening, which, in the judgment of the investigator, would make the patient inappropriate for this clinical trial ;
- 13 History or conditions of any of the following at screening or run-in: those with a history or clinical evidence of acute or chronic pancreatitis;
- 14 History or condition of any of the following at screening or run-in: poorly controlled blood pressure, ie, systolic blood pressure (SBP) > 160 mmHg and/or diastolic blood pressure (DBP) > 100 mmHg ;
- 15 Use of any of the following medications or therapies prior to Screening or Run-in: Dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists prior to Screening or within 3 months prior to Run-in ;
- 16 Use of any of the following drugs or therapies before screening or run-in: Use of other drugs that may affect glucose metabolism, such as systemic glucocorticoids, growth hormone, etc., before screening or within 3 months before run-in;
- 17 Use of any of the following drugs or therapies before screening or run-in: those with cumulative use of insulin and its analogues for more than 28 days in the previous year (except for gestational diabetes treated with insulin and its analogues)
- 18. When screening, any one of the laboratory inspection indicators meets the following standards: ALT/AST> 2.5ULN; Total bilirubin> 2.0ULN; Subjects with current severe renal disease, or eGFR (CKD-EPI2012Scr-CysC) ≤ 60 mL/min/1.73 m2;TG)>5.6mmol/L;Blood amylase>>1.5ULN;HGB<10.0g/dL(100g/L);
- 19 Any positive HCV antibody, HIV antibody or Treponema pallidum antibody at screening; positive hepatitis B HBsAg, additionally test hepatitis B virus load (HBV-DNA), positive HBsAg and HBV-DNA higher than the lower limit of detection in the local laboratory;
- 20 .The patient may have any contraindications, allergies or hypersensitivity to Test drug (including study drug and placebo) or its excipients, DPP4 drugs
- 21.Patients with a history of joint pain after taking DPP-4 inhibitors ;
- 22.Patients who have received 3 or more times of clinical trial drugs within the past year, or patients who have received 1 time of clinical trial drugs within 1 month before screening ;
- 23 Female subjects who are pregnant, lactating, or planning pregnancy during the study ;
- 24 Male and female subjects of childbearing potential who do not agree to practice contraception during the study. Females of childbearing potential (including those less than 2 years postmenopausal) must agree to practice a reliable method of contraception (e.g., transdermal contraceptive patch, implantable long-acting solution for injection, contraceptive ring, subdermal implant, intrauterine device, or double barrier method (diaphragm+condom) throughout the entire study period) ;
- 25 One or more grade 3 hypoglycemic events without obvious cause during the run-in period ;
- 26 Medication compliance with the lozenge was < 75% or > 125% during the run-in period ;
- 27 The subject has any other factors that the investigator considers inappropriate for the trial 。
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador de placebos: Grupo de control con placebo
|
placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
|
Experimental: Yogliptin 200mg group
|
Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
|
Experimental: Yogliptin 400mg group
|
Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Cambio de HbA1c desde el inicio en la semana 24
Periodo de tiempo: Línea de base y semana 24
|
Cambio desde el inicio en la hemoglobina A1c (HbA1c) en la semana 24
|
Línea de base y semana 24
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Cambio de FPG desde el inicio en la semana 24 y la semana 52
Periodo de tiempo: Línea de base, semana 24 y semana 52
|
Línea de base, semana 24 y semana 52
|
2h-PPG Change From Baseline at Week 24 and Week 44 and Week 52
Periodo de tiempo: Baseline, week 24 and Week 44 and Week 52
|
Baseline, week 24 and Week 44 and Week 52
|
Percentage of Patients With HbA1c <6.5%
Periodo de tiempo: Time Frame: Baseline, week 24 and week 52
|
Time Frame: Baseline, week 24 and week 52
|
Porcentaje de pacientes con HbA1c <7,0 %
Periodo de tiempo: Línea de base, semana 24 y semana 52
|
Línea de base, semana 24 y semana 52
|
blood pressure Change From Baseline at Week 24 and Week 52
Periodo de tiempo: Baseline, week 24 and week 52
|
Baseline, week 24 and week 52
|
Cambio de peso desde el inicio en la semana 24 y la semana 52
Periodo de tiempo: Línea de base, semana 24 y semana 52
|
Línea de base, semana 24 y semana 52
|
Fasting lipids From Baseline at Week 24 and Week 52
Periodo de tiempo: Baseline, week 24 and week 52
|
Baseline, week 24 and week 52
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Director de estudio: Lixin Guo, Beijing Hospital
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
1 de enero de 2022
Finalización primaria (Anticipado)
31 de diciembre de 2024
Finalización del estudio (Anticipado)
31 de diciembre de 2024
Fechas de registro del estudio
Enviado por primera vez
31 de marzo de 2022
Primero enviado que cumplió con los criterios de control de calidad
31 de marzo de 2022
Publicado por primera vez (Actual)
8 de abril de 2022
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
20 de abril de 2022
Última actualización enviada que cumplió con los criterios de control de calidad
19 de abril de 2022
Última verificación
1 de abril de 2022
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ChengduEastonBiopharma
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Diabetes tipo 2
-
Jin-Hee AhnAsan Medical CenterDesconocidoAmplificación del gen HER-2 | Sobreexpresión de proteína HER-2
-
The University of Tennessee, KnoxvilleTerminadoProfesores de Matemáticas (Grados 2-8) | Estudiantes de Matemáticas (Grados 2-8)Estados Unidos
-
PowderMedTerminado
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.DesconocidoTumor solido | Amplificación del gen HER-2 | Mutación del gen HER2 | Sobreexpresión de proteína HER-2Porcelana
-
Argorna Pharmaceuticals Co., LTDTerminado
-
Argorna Pharmaceuticals Co., LTDTerminado
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Activo, no reclutando
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical...Activo, no reclutando
-
Arcturus Therapeutics, Inc.Terminado
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsTerminado
Ensayos clínicos sobre placebo group
-
University of LisbonAssociacao Protectora dos Diabeticos de PortugalTerminado
-
Arizona Oncology ServicesDesconocidoCáncer de mama localizado | Cáncer de próstata localizado | Pacientes que reciben radioterapia de haz externoEstados Unidos
-
University of TennesseeNational Cancer Institute (NCI); Regional One HealthReclutamientoPérdida de peso | Sobrepeso y Obesidad | Comportamiento, SaludEstados Unidos
-
Boston Children's HospitalTerminadoEstrés Psicológico | Problema de aculturaciónEstados Unidos
-
Amsterdam UMC, location VUmcRed Cross Hospital BeverwijkTerminadoCicatriz Hipertrófica | QueloidePaíses Bajos
-
Aydin Adnan Menderes UniversityAún no reclutando
-
Aydin Adnan Menderes UniversityAún no reclutandoEducación | Estudiantes de EnfermeríaPavo
-
Amasya UniversityAún no reclutandoSoledad | Danzaterapia | Auto abandonoPavo
-
Centre hospitalier de l'Université de Montréal...University Health Network, Toronto; University of British Columbia; McGill University y otros colaboradoresReclutamientoEnfermedades urológicasCanadá, Estados Unidos
-
Shanghai MicroPort Rhythm MedTech Co., Ltd.ReclutamientoPerforación de la arteria coronariaPorcelana